Michael R Jacobs

List of Publications by Year in Descending Order

92 papers	2,923 citations	30 h-index	51 g-index
97 ext. papers	3,467 ext. citations	6.1 avg, IF	4.94 L-index

#	Paper	IF	Citations
92	Accuracy of Direct Antimicrobial Susceptibility of Gram-Negative Bacteria from Positive Blood Cultures using MicroScan System and Value of Using Expert Rules for -Lactam Agents.. *Antimicrobial Agents and Chemotherapy*, **2022**, aac0214821	5.9	0
91	Multicenter Evaluation of the Acuitas AMR Gene Panel for Detection of an Extended Panel of Antimicrobial Resistance Genes among Bacterial Isolates.. *Journal of Clinical Microbiology*, **2022**, JCM0209821	9.7	0
90	Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing.. *PLoS ONE*, **2022**, 17, e0265129	3.7	0
89	Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant Pseudomonas aeruginosa: Inhibitor-Resistant -Lactamases and Their Increasing Importance.. *Antimicrobial Agents and Chemotherapy*, **2022**, e0179021	5.9	
88	Recent advances in rapid antimicrobial susceptibility testing systems. *Expert Review of Molecular Diagnostics*, **2021**, 21, 563-578	3.8	2
87	Detection of mcr-1 gene in a clinical Escherichia coli strain in North Carolina: first report. *Journal of Global Antimicrobial Resistance*, **2021**, 25, 154-156	3.4	1
86	: intriguing aerotolerant gut anaerobe with emerging antimicrobial resistance and pathogenic and probiotic roles in human health. *Gut Microbes*, **2021**, 13, 1922241	8.8	17
85	A -lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp. *European Journal of Medicinal Chemistry*, **2021**, 220, 113436	6.8	8
84	Bacterial contamination and septic transfusion reaction rates associated with platelet components before and after introduction of primary culture: experience at a US Academic Medical Center 1991 through 2017. *Transfusion*, **2020**, 60, 974-985	2.9	7
83	A -Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli. *Journal of Medicinal Chemistry*, **2020**, 63, 5990-6002	8.3	10
82	Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo--Lactamase-1. *Clinical Infectious Diseases*, **2020**, 71, 1095-1098	11.6	34
81	AbGRI4, a novel antibiotic resistance island in multiply antibiotic-resistant Acinetobacter baumannii clinical isolates. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 2760-2768	5.1	3
80	A two-part phase 1 study to establish and compare the safety and local tolerability of two nasal formulations of XF-73 for decolonisation of Staphylococcus aureus: A previously investigated 0.5mg/g viscosified gel formulation versus a modified formulation. *Journal of Global Antimicrobial Resistance*, **2020**, 21, 171-180	3.4	3
79	ARGONAUT II Study of the Activity of Plazomicin against Carbapenemase-Producing Klebsiella pneumoniae. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	8
78	Association of Laboratory Methods, Colonization Density, and Age With Detection of Streptococcus pneumoniae in the Nasopharynx. *American Journal of Epidemiology*, **2019**, 188, 2110-2119	3.8	8
77	Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	19
76	Targeting Multidrug-Resistant spp.: Sulbactam and the Diazabicyclooctenone -Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent. *MBio*, **2019**, 10,	7.8	35

75	Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam-β-Lactamase Inhibitor Combination. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	44
74	Rapid Replacement of Acinetobacter baumannii Strains Accompanied by Changes in Lipooligosaccharide Loci and Resistance Gene Repertoire. *MBio*, **2019**, 10,	7.8	16
73	Review of current transfusion therapy and blood banking practices. *Blood Reviews*, **2019**, 38, 100593	11.1	22
72	Complete Genome Sequence of a Parabacteroides distasonis Strain (CavFT hAR46) Isolated from a Gut Wall-Cavitating Microlesion in a Patient with Severe Crohn's Disease. *Microbiology Resource Announcements*, **2019**, 8,	1.3	9
71	ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and with Defined Extended-Spectrum β-Lactamases and Carbapenemases. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	57
70	Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV. *Clinical Infectious Diseases*, **2019**, 68, 1823-1830	11.6	27
69	Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. *Journal of Medicinal Chemistry*, **2018**, 61, 4067-4086	8.3	77
68	Prolonged Course of Salmonella Pelvic Osteomyelitis in an Immunocompetent African American Child: A Case Report and Review of the Literature. *Journal of Pediatric Infectious Diseases*, **2018**, 13, 084-088	0.4	1
67	Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by Carbapenemase-Producing. *Open Forum Infectious Diseases*, **2018**, 5, ofy054	1	7
66	Transcriptome Remodeling of during Infection and Treatment. *MBio*, **2017**, 8,	7.8	23
65	Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	143
64	Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	136
63	Multicenter Clinical Evaluation of BacT/Alert Virtuo Blood Culture System. *Journal of Clinical Microbiology*, **2017**, 55, 2413-2421	9.7	29
62	Nosocomial Outbreak of Extensively Drug-Resistant Acinetobacter baumannii Isolates Containing Carried on a Plasmid. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	24
61	Failure to Communicate: Transmission of Extensively Drug-Resistant bla OXA-237-Containing Acinetobacter baumannii-Multiple Facilities in Oregon, 2012-2014. *Infection Control and Hospital Epidemiology*, **2017**, 38, 1335-1341	2	11
60	Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	36
59	Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III. *Journal of Clinical Microbiology*, **2017**, 55, 134-144	9.7	22
58	AAI101, a Novel β-Lactamase Inhibitor: Microbiological and Enzymatic Profiling. *Open Forum Infectious Diseases*, **2017**, 4, S375-S375	1	7

57	Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. *Blood*, **2016**, 127, 496-502	2.2	125
56	Whole-Genome Comparative Analysis of Two Carbapenem-Resistant ST-258 Klebsiella pneumoniae Strains Isolated during a North-Eastern Ohio Outbreak: Differences within the High Heterogeneity Zones. *Genome Biology and Evolution*, **2016**, 8, 2036-43	3.9	22
55	Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture. *Tuberculosis*, **2016**, 98, 92-6	2.6	11
54	Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatment. *Genome Medicine*, **2016**, 8, 26	14.4	48
53	Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. *Clinical Infectious Diseases*, **2016**, 62, 181-9	11.6	44
52	Methylfolate Trap Promotes Bacterial Thymineless Death by Sulfa Drugs. *PLoS Pathogens*, **2016**, 12, e1005949	7.5	24
51	Benefit-risk Evaluation for Diagnostics: A Framework (BED-FRAME). *Clinical Infectious Diseases*, **2016**, 63, 812-7	11.6	18
50	The Changing Role of the Clinical Microbiology Laboratory in Defining Resistance in Gram-negatives. *Infectious Disease Clinics of North America*, **2016**, 30, 323-345	6.5	12
49	Molecular Diversity and Plasmid Analysis of KPC-Producing Escherichia coli. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 4073-81	5.9	27
48	Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases. *Diagnostic Microbiology and Infectious Disease*, **2015**, 82, 65-9	2.9	37
47	Complete sequence of a bla(KPC)-harboring cointegrate plasmid isolated from Escherichia coli. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 2956-9	5.9	16
46	Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing Klebsiella pneumoniae. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 4375-8	5.9	14
45	SISPA-Seq for rapid whole genome surveys of bacterial isolates. *Infection, Genetics and Evolution*, **2015**, 32, 191-8	4.5	10
44	Sulfamethoxazole susceptibility of Mycobacterium tuberculosis isolates from HIV-infected Ugandan adults with tuberculosis taking trimethoprim-sulfamethoxazole prophylaxis. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 5844-6	5.9	4
43	Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 4035-41	5.9	100
42	Identification of occult Fusobacterium nucleatum central nervous system infection by use of PCR-electrospray ionization mass spectrometry. *Journal of Clinical Microbiology*, **2014**, 52, 3462-4	9.7	6
41	Extensively drug-resistant pseudomonas aeruginosa isolates containing blaVIM-2 and elements of Salmonella genomic island 2: a new genetic resistance determinant in Northeast Ohio. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 5929-35	5.9	28
40	Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine. *Diagnostic Microbiology and Infectious Disease*, **2014**, 80, 19-25	2.9	35

39	Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection test. *Transfusion*, **2011**, 51, 2573-82	2.9	91
38	Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. *Journal of Clinical Microbiology*, **2008**, 46, 982-90	9.7	67
37	Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets. *Clinical Infectious Diseases*, **2008**, 46, 1214-20	11.6	118
36	Nasopharyngeal carriage of respiratory pathogens in children undergoing pressure equalization tube placement in the era of pneumococcal protein conjugate vaccine use. *Laryngoscope*, **2007**, 117, 295-8	3.6	16
35	Oral beta-lactams applied to uncomplicated infections of skin and skin structures. *Diagnostic Microbiology and Infectious Disease*, **2007**, 57, 55S-65S	2.9	18
34	Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. *Expert Opinion on Pharmacotherapy*, **2006**, 7, 1957-66	4	34
33	Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. *Transfusion*, **2006**, 46, 719-30	2.9	73
32	Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles. *Expert Review of Anti-Infective Therapy*, **2005**, 3, 353-60	5.5	2
31	Enhancement of a culture-based bacterial detection system (eBDS) for platelet products based on measurement of oxygen consumption. *Transfusion*, **2005**, 45, 984-93	2.9	36
30	Fluoroquinolones as chemotherapeutics against mycobacterial infections. *Current Pharmaceutical Design*, **2004**, 10, 3213-20	3.3	30
29	In vitro activity of the new quinolone WCK 771 against staphylococci. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 3338-42	5.9	36
28	Streptococcus pneumoniae: epidemiology and patterns of resistance. *The American Journal of Medicine: Supplement*, **2004**, 117 Suppl 3A, 3S-15S		29
27	Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 U S Surveillance Study. *Clinics in Laboratory Medicine*, **2004**, 24, 503-30	2.1	44
26	Mechanisms of resistance among respiratory tract pathogens. *Clinics in Laboratory Medicine*, **2004**, 24, 419-53	2.1	7
25	Antimicrobial resistance among pediatric respiratory tract infections: clinical challenges. *Seminars in Pediatric Infectious Diseases*, **2004**, 15, 5-20		20
24	Macrolide resistance: an increasing concern for treatment failure in children. *Pediatric Infectious Disease Journal*, **2003**, 22, S131-8	3.4	44
23	The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. *Journal of Antimicrobial Chemotherapy*, **2003**, 52, 229-46	5.1	365
22	Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 Gram-positive cocci. *Journal of Antimicrobial Chemotherapy*, **2003**, 52, 809-12	5.1	19

21	Effects of various test media on the activities of 21 antimicrobial agents against Haemophilus influenzae. *Journal of Clinical Microbiology*, **2002**, 40, 3269-76	9.7	13
20	Prevention of otitis media: role of pneumococcal conjugate vaccines in reducing incidence and antibiotic resistance. *Journal of Pediatrics*, **2002**, 141, 287-93	3.6	11
19	Release of complement regulatory proteins from ocular surface cells in infections. *Current Eye Research*, **2000**, 21, 856-66	2.9	11
18	Evaluation of Etest for susceptibility testing of Mycobacterium tuberculosis. *Journal of Clinical Microbiology*, **2000**, 38, 3834-6	9.7	18
17	Activity of HMR 3647 compared to those of six compounds against 235 strains of Enterococcus faecalis. *Antimicrobial Agents and Chemotherapy*, **1999**, 43, 166-8	5.9	11
16	Streptococcus pneumoniae: Activity of Newer Agents Against Penicillin-Resistant Strains. *Current Infectious Disease Reports*, **1999**, 1, 13-21	3.9	6
15	Activity of quinolones against mycobacteria. *Drugs*, **1999**, 58 Suppl 2, 19-22	12.1	30
14	Antianaerobic Activity of Gatifloxacin. *Drugs*, **1999**, 58, 113-116	12.1	1
13	Clinafloxacin Antibacterial Activity. *Drugs*, **1999**, 58, 217-221	12.1	3
12	Levofloxacin and Clarithromycin Antipneumococcal Activity. *Drugs*, **1999**, 58, 366-368	12.1	
11	Antipneumococcal Activity of Gatifloxacin by Time-Kill Methodology. *Drugs*, **1999**, 58, 369-371	12.1	
10	Antipneumococcal Activity of Gatifloxacin by Agar Dilution MIC. *Drugs*, **1999**, 58, 372-373	12.1	
9	Postantibiotic Effect of Levofloxacin Against Pneumococci. *Drugs*, **1999**, 58, 378-380	12.1	1
8	Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. *Journal of Antimicrobial Chemotherapy*, **1995**, 35, 230-2	5.1	88
7	Activity of quinolones against mycobacteria. *Drugs*, **1995**, 49 Suppl 2, 67-75	12.1	23
6	Adhesion of Staphylococcus epidermidis to biomedical polymers: contributions of surface thermodynamics and hemodynamic shear conditions. *Journal of Biomedical Materials Research Part B*, **1995**, 29, 485-93		59
5	Antimicrobial activity and in vitro corneal epithelial toxicity of antimicrobial agents for gram-positive corneal pathogens. *Current Eye Research*, **1993**, 12, 603-8	2.9	8
4	Corynebacterium striatum: a diphtheroid with pathogenic potential. *Clinical Infectious Diseases*, **1993**, 17, 21-5	11.6	56

3	Topical fluoroquinolones: antimicrobial activity and in vitro corneal epithelial toxicity. *Current Eye Research*, **1991**, 10, 557-63	2.9	47
2	Prevalence and significance of methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis. *Pediatric Pulmonology*, **1988**, 4, 159-63	3.5	49
1	Synergy of amoxycillin combined with clavulanate and YTR 830 in experimental infections in mice. *Journal of Antimicrobial Chemotherapy*, **1986**, 18, 271-6	5.1	11